Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × NSCLC × Afatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 3 Carcinoma, Non-Small-Cell Lung 3 Pancreatic Neoplasms 2 Colorectal Neoplasms 2 Stomach Neoplasms 1 Rhabdomyosarcoma 1 Neuroectodermal Tumors 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Fanconi Anemia 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Pemetrexed 2 Carboplatin 2 sulindac sulfone 1 pembrolizumab 1 nimotuzumab 1 aflutinib 1 Clinical Trials, Phase I as Topic 1 BID protein, human 1 Antigens 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡